Regeneron (REGN) Stock Forecast & Price Target

Compare

5,025 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

17 Buy

4 Hold

1 Sell

Based on 22 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$751.00

▲(15.02% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $751.00 with a high forecast of $890.00 and a low forecast of $595.00. The average price target represents a 15.02% change from the last price of $652.91.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"489":"$489","766":"$766","1043":"$1,043","627.5":"$627.5","904.5":"$904.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":890,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$890.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":751,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$751.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$595.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[489,627.5,766,904.5,1043],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,599.94,622.2523076923078,644.5646153846154,666.8769230769232,689.1892307692308,711.5015384615385,733.8138461538462,756.1261538461539,778.4384615384615,800.7507692307693,823.0630769230769,845.3753846153846,867.6876923076923,{"y":890,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,599.94,611.5600000000001,623.1800000000001,634.8000000000001,646.4200000000001,658.0400000000001,669.6600000000001,681.28,692.9,704.52,716.14,727.76,739.38,{"y":751,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,599.94,599.5600000000001,599.1800000000001,598.8000000000001,598.4200000000001,598.0400000000001,597.6600000000001,597.28,596.9,596.52,596.14,595.76,595.38,{"y":595,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1042.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":840,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":759.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":709.29,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":670.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":696.65,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":615.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":588.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":534.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":558.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":577.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":599.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$890.00

Average Price Target$751.00

Lowest Price Target$595.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tim Anderson

Bank of America Securities

$543→$627

Sell

-3.97%

Downside

Reiterated

10/29/25

Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks

Cory Kasimov

Evercore ISI

$750

Buy

14.87%

Upside

Reiterated

10/29/25

Evercore ISI Remains a Buy on Regeneron (REGN)

Mohit Bansal

Wells Fargo

$580→$615

Hold

-5.81%

Downside

Reiterated

10/29/25

Regeneron price target raised to $615 from $580 at Wells FargoRegeneron price target raised to $615 from $580 at Wells Fargo

Tyler Van Buren

TD Cowen

$780→$800

Buy

22.53%

Upside

Reiterated

10/29/25

Regeneron: Strong Financial Performance and Future Growth Potential Drive Buy RatingWe will know more by late November (the original PDUFA), as there are multiple scenarios which depend on the FDA issuing a CRL and overall flexibility.Global The COPD And CSU As discussed here, Q3 WW Dupi sales were $4.86B (+12% Q/Q; +27% Y/Y), which were 5% above consensus. Dupi continues to hold the #1 share of TRx share across all established indications (AD, asthma, CRSwNP, EoE, and PN). Demand continues to drive sales growth, with Regeneron reporting that over 1.3MM patients globally are on Dupi.

Akash Tewari

Jefferies

$831→$870

Buy

33.25%

Upside

Reiterated

10/29/25

Regeneron (REGN) Gets a Buy from Jefferies

William Pickering

Bernstein

$781→$818

Buy

25.29%

Upside

Assigned

10/29/25

Bernstein Sticks to Its Buy Rating for Regeneron (REGN)

Geoff Meacham

Citi

$660→$700

Buy

7.21%

Upside

Reiterated

10/29/25

Regeneron price target raised to $700 from $660 at CitiRegeneron price target raised to $700 from $660 at Citi

Srikripa Devarakonda

Truist Financial

$812

Buy

24.37%

Upside

Reiterated

10/29/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

Evan Seigerman

BMO Capital

$640→$725

Buy

11.04%

Upside

Reiterated

10/29/25

Regeneron price target raised to $725 from $640 at BMO CapitalRegeneron price target raised to $725 from $640 at BMO Capital

Carter Gould

Cantor Fitzgerald

$678→$740

Buy

13.34%

Upside

Reiterated

10/29/25

Cantor Fitzgerald Sticks to Their Buy Rating for Regeneron (REGN)

John Newman

Canaccord Genuity

$850

Buy

30.19%

Upside

Reiterated

10/29/25

Analysts Offer Insights on Healthcare Companies: Gyre Therapeutics (NASDAQ: GYRE), Regeneron (NASDAQ: REGN) and UnitedHealth (NYSE: UNH)

Brian Skorney

Robert W. Baird

$587→$637

Hold

-2.44%

Downside

Reiterated

10/29/25

Regeneron price target raised to $637 from $587 at BairdRegeneron price target raised to $637 from $587 at Baird

Yatin Suneja

Guggenheim

$815→$865

Buy

32.48%

Upside

Reiterated

10/28/25

Regeneron price target raised to $865 from $815 at GuggenheimRegeneron price target raised to $865 from $815 at Guggenheim

Terence Flynn

Morgan Stanley

$756→$767

Buy

17.47%

Upside

Reiterated

10/28/25

Regeneron price target raised to $767 from $756 at Morgan StanleyRegeneron price target raised to $767 from $756 at Morgan Stanley

Brian Abrahams

RBC Capital

$704→$708

Hold

8.44%

Upside

Reiterated

10/28/25

RBC Capital Keeps Their Hold Rating on Regeneron (REGN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tim Anderson

Bank of America Securities

$543→$627

Sell

-3.97%

Downside

Reiterated

10/29/25

Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks

Cory Kasimov

Evercore ISI

$750

Buy

14.87%

Upside

Reiterated

10/29/25

Evercore ISI Remains a Buy on Regeneron (REGN)

Mohit Bansal

Wells Fargo

$580→$615

Hold

-5.81%

Downside

Reiterated

10/29/25

Regeneron price target raised to $615 from $580 at Wells FargoRegeneron price target raised to $615 from $580 at Wells Fargo

Tyler Van Buren

TD Cowen

$780→$800

Buy

22.53%

Upside

Reiterated

10/29/25

Akash Tewari

Jefferies

$831→$870

Buy

33.25%

Upside

Reiterated

10/29/25

Regeneron (REGN) Gets a Buy from Jefferies

William Pickering

Bernstein

$781→$818

Buy

25.29%

Upside

Assigned

10/29/25

Bernstein Sticks to Its Buy Rating for Regeneron (REGN)

Geoff Meacham

Citi

$660→$700

Buy

7.21%

Upside

Reiterated

10/29/25

Regeneron price target raised to $700 from $660 at CitiRegeneron price target raised to $700 from $660 at Citi

Srikripa Devarakonda

Truist Financial

$812

Buy

24.37%

Upside

Reiterated

10/29/25

Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)

Evan Seigerman

BMO Capital

$640→$725

Buy

11.04%

Upside

Reiterated

10/29/25

Regeneron price target raised to $725 from $640 at BMO CapitalRegeneron price target raised to $725 from $640 at BMO Capital

Carter Gould

Cantor Fitzgerald

$678→$740

Buy

13.34%

Upside

Reiterated

10/29/25

Cantor Fitzgerald Sticks to Their Buy Rating for Regeneron (REGN)

John Newman

Canaccord Genuity

$850

Buy

30.19%

Upside

Reiterated

10/29/25

Analysts Offer Insights on Healthcare Companies: Gyre Therapeutics (NASDAQ: GYRE), Regeneron (NASDAQ: REGN) and UnitedHealth (NYSE: UNH)

Brian Skorney

Robert W. Baird

$587→$637

Hold

-2.44%

Downside

Reiterated

10/29/25

Regeneron price target raised to $637 from $587 at BairdRegeneron price target raised to $637 from $587 at Baird

Yatin Suneja

Guggenheim

$815→$865

Buy

32.48%

Upside

Reiterated

10/28/25

Regeneron price target raised to $865 from $815 at GuggenheimRegeneron price target raised to $865 from $815 at Guggenheim

Terence Flynn

Morgan Stanley

$756→$767

Buy

17.47%

Upside

Reiterated

10/28/25

Regeneron price target raised to $767 from $756 at Morgan StanleyRegeneron price target raised to $767 from $756 at Morgan Stanley

Brian Abrahams

RBC Capital

$704→$708

Hold

8.44%

Upside

Reiterated

10/28/25

RBC Capital Keeps Their Hold Rating on Regeneron (REGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

12/20 ratings generated profit

Average Return

+0.60%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.60% per trade.

3 Months

xxx

Success Rate

17/30 ratings generated profit

Average Return

-0.18%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.67% of your transactions generating a profit, with an average return of -0.18% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

17/25 ratings generated profit

Average Return

+10.61%

reiterated a buy rating 30 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 68.00% of your transactions generating a profit, with an average return of +10.61% per trade.

2 Years

xxx

Success Rate

17/25 ratings generated profit

Average Return

+11.79%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.00% of your transactions generating a profit, with an average return of +11.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 49 Buy Ratings, 7 Hold Ratings, and 2 Sell Ratings. REGN average Analyst price target in the past 3 months is 751.00.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $10.56 with a range of $8.20 to $12.92. The previous quarter’s EPS was $11.83. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year REGN has Preformed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.76B with a range of $3.42B to $4.11B. The previous quarter’s sales results were $3.75B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year REGN has Preformed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron’s 12-month average price target is 751.00.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron has 15.02% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron has a consensus rating of Moderate Buy which is based on 17 buy ratings, 4 hold ratings and 1 sell ratings.

What is Regeneron’s price target?

The average price target for Regeneron is 751.00. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $890.00 ,the lowest forecast is $595.00. The average price target represents 15.02% Increase from the current price of $652.91.

What do analysts say about Regeneron?

Regeneron’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts